Journal: Pharmaceuticals

Article Title: BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

doi: 10.3390/ph12010041

Figure Lengend Snippet: γ-Secretase inhibitors ( 1 – 2 ) advanced in late-stage clinical trials.

Article Snippet: Independently from Wyeth, AstraZeneca also developed a series of inhibitors based on compound 39 , herein represented by compounds 41 and 42 in .

Techniques: Clinical Proteomics

Journal: Pharmaceuticals

Article Title: BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

doi: 10.3390/ph12010041

Figure Lengend Snippet: Structures and activity of acyl guanidine-based BACE-1 inhibitors 18–21 .

Article Snippet: Independently from Wyeth, AstraZeneca also developed a series of inhibitors based on compound 39 , herein represented by compounds 41 and 42 in .

Techniques: Activity Assay

Journal: Pharmaceuticals

Article Title: BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

doi: 10.3390/ph12010041

Figure Lengend Snippet: Acyl guanidine-based BACE-1 inhibitors developed by BMS .

Article Snippet: Independently from Wyeth, AstraZeneca also developed a series of inhibitors based on compound 39 , herein represented by compounds 41 and 42 in .

Techniques:

Journal: Pharmaceuticals

Article Title: BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

doi: 10.3390/ph12010041

Figure Lengend Snippet: Merck’s aminoimidazole-based inhibitors.

Article Snippet: Independently from Wyeth, AstraZeneca also developed a series of inhibitors based on compound 39 , herein represented by compounds 41 and 42 in .

Techniques:

Journal: Pharmaceuticals

Article Title: BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease

doi: 10.3390/ph12010041

Figure Lengend Snippet: Aminoimidazole-based inhibitors 41 – 42 developed by AstraZeneca.

Article Snippet: Independently from Wyeth, AstraZeneca also developed a series of inhibitors based on compound 39 , herein represented by compounds 41 and 42 in .

Techniques: